Long-term outcomes and biomarker analyses of two neoadjuvant immunotherapy clinical trials in melanoma patients support the clinical benefit of this treatment approach and uncover prognostic correlates of response.
- E. A. Rozeman
- E. P. Hoefsmit
- C. U. Blank
